# DESCRIPTION

## STATEMENT OF FEDERALLY FUNDED RESEARCH

- acknowledge government funding

## TECHNICAL FIELD OF THE INVENTION

- define technical field

## BACKGROUND OF THE INVENTION

- describe SARS-CoV-2 infection
- discuss limitations of current treatments

## SUMMARY OF THE INVENTION

- introduce method for treating viral infections
- describe inhibitor of SARS-CoV-2 binding to L-SIGN
- outline pharmaceutical composition and administration
- discuss treatment of liver and lymph node dysfunction
- summarize various embodiments of the invention

## DETAILED DESCRIPTION OF THE INVENTION

- define terms
- explain terminology
- describe therapeutically effective amount
- outline dosage and administration
- discuss carrier solutions
- define subject
- explain pharmaceutically acceptable
- describe effective dose
- outline conventional methods
- motivate SARS-CoV-2 research
- describe materials and methods
- outline protein purification and cell culture
- list reagents and antibodies
- describe SARS-CoV-2 pseudovirus production and infection inhibition assay
- outline flow cytometric analysis
- summarize western blotting and lectin blotting
- describe histology and microscopy
- outline glycan structural analysis
- summarize statistics
- describe study approval
- motivate Ca2+-dependent binding of L-SIGN to SARS-CoV-2 spike protein
- describe Spike/Fc binding to L-SIGN- and ACE2-expressing cells
- summarize CoV2-type infection of cells expressing ACE2 or L-SIGN
- compare L-SIGN with DC-SIGN
- introduce L-SIGN as a novel SARS-CoV-2 receptor
- describe L-SIGN's internalization motifs
- analyze glycan structures of Spike/Fc
- demonstrate L-SIGN binding to high-mannose N-glycan on Spike/Fc
- investigate EPN motif of L-SIGN in N-glycan recognition
- express and characterize L-SIGN/Fc
- examine L-SIGN expression in human tissues
- profile L-SIGN expression in cultured primary LSECs and LECs
- detect SARS-CoV-2 in LSECs of COVID-19 patient liver autopsy samples
- analyze co-expression of CLEC4M with VWF, F8, and PLAT in LSECs
- block L-SIGN function to reduce CoV2-type infection
- discuss L-SIGN as a type II transmembrane protein
- describe phylogenetic tree of L-SIGN
- compare L-SIGN and DC-SIGN in mediating infections
- discuss SARS-CoV-2 spike protein binding to L-SIGN
- analyze N-glycans on RBD N343
- discuss ACE2 as a documented entry receptor for SARS-CoV-2
- describe coagulopathy and thrombosis in severe COVID-19 patients
- discuss endothelial cell activation and secretion of VWF and FVIII
- propose L-SIGN-mediated activation of LSECs and LECs
- summarize L-SIGN as a tissue-specific receptor for SARS-CoV-2

